May 12, 2025 - 14:37
Mike Heffernan has been appointed as the new Chairman of the Board at Avalo Therapeutics, marking a significant leadership change for the company. In addition to this appointment, the company is anticipating the release of topline data from its Phase 2 LOTUS trial for AVTX-009, a treatment aimed at addressing hidradenitis suppurativa, with results expected in 2026.
As of March 31, 2025, Avalo reported a robust cash position of approximately $125 million, which is projected to provide sufficient financial runway into 2027. This funding will allow the company to continue its focus on developing innovative therapies for immune dysregulation, with the potential to extend operations into 2028 if necessary.
These updates reflect Avalo's commitment to advancing its clinical programs and enhancing shareholder value as it navigates the complexities of the biotechnology landscape. The leadership transition and solid financial standing position the company for future growth and success in the coming years.
